Non-Rx drug exclusion from Canadian patented drug price controls bill sought by NDMAC.
This article was originally published in The Tan Sheet
Executive Summary
CANADIAN NON-Rx DRUG EXCLUSION FROM BILL C-91 SOUGHT BY NDMAC in a brief submitted March 27 to the Parliamentary Committee on Industry. The committee is reviewing Bill C-91, a 1993 act amending Canada's patent laws by establishing a Patented Medicine Prices Review Board (PMPRB) to set price controls for patented drugs, both prescription and nonprescription. Although the bulk of patented drugs in Canada are prescription, there is a movement under way in the country to expand the board's jurisdiction to nonpatented drugs, which would affect an additional 8,000-10,000 non-Rx products.